Other studies combine nivolumab (anti-PD-1) with the ADC BMS-986148 (208, 310), composed of a mAb against the cell surface glycoprotein mesothelin (MSLN), conjugated to an as of yet undisclosed cytotoxic drug, for the treatment of mesothelioma, NSCLC, ovarian cancer, pancreatic cancer, and gastric cancer (NCT02341625). The gene discussed is MSLN; the disease is ovarian cancer.